ESC 2017
Does Oxygen Therapy Reduce Mortality in Suspected Acute MI?
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
Your search for supplemental oxygen returned 87 results
News
Tocilizumab Does Not Prevent Intubation, Death in COVID-19
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients.
Drugs in the Pipeline
Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline, News
FDA Issues EUA to Baricitinib Plus Remdesivir for Hospitalized COVID-19 Patients
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
Drugs in the Pipeline, News
FDA Greenlights Study to Evaluate Opaganib in Patients With Moderate to Severe COVID-19
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
News
NIH Trial Evaluating Hydroxychloroquine for COVID-19 Underway
Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.
Drugs in the Pipeline
NIH: Remdesivir Plus Interferon Beta-1a Being Evaluated for COVID-19
The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.
ACAAI 2020
Atopic Dermatitis Does Not Appear to Affect COVID-19 Severity
Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Drugs in the Pipeline
Trials Testing Convalescent Plasma for COVID-19 Expanded
Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.
